Curevac Vaccine Covid Efficacy. CureVac said it would abandon its application for approval from the European Medicines Agency for its first COVID-19 vaccine candidate CVnCoV after late-stage trials delivered disappointing. 200 AM EDT Reuters.
CureVac COVID-19 vaccine records only 48 efficacy in final trial readout. CureVacs COVID-19 vaccine only had 48 percent efficacy. The vaccine candidate chosen for first clinical development CVnCoV is an optimized non-chemically modified mRNA encoding the prefusion stabilized full-length spike protein of the SARS-CoV-2 virus and formulated within Lipid Nanoparticles LNPs.
German biotech CureVac plans to seek regulatory approval for its experimental coronavirus vaccine despite full results from a large international study confirming a disappointing overall efficacy against COVID-19 of just 48.
CureVac said it would abandon its application for approval from the European Medicines Agency for its first COVID-19 vaccine candidate CVnCoV after late-stage trials delivered disappointing. The biotechnology company CureVac has announced that its Phase IIbIII clinical trial of the COVID-19 vaccine candidate CVnCoV demonstrates an interim efficacy of 47. The German company CureVac announced on Tuesday that it was withdrawing its mRNA vaccine for Covid-19 from the approval process in Europe. In June CureVac said its vaccine was 47 effective in a late stage trial and this month it cancelled two manufacturing deals after other drugmakers boosted their own production.
